Currently, genetic syndromes with a high incidence of pancreatic cancer are being targeted for screening [22], [23] using blood proteomic profiling [24], serum biomarkers, such as amyloid A [25], RCAS1 [26], CA 19-9, etc. Translational studies are underway to discover novel molecular biomarkers such as up-regulated genes and over-expressed proteins specific for pancreatic carcinomas that could be detected in serum and pancreatic juice. This evidence concerns the gene EBAG9 and pancreatic neoplasm.